Arithmetic Abilities in Children With 22q11.2DS

Study of Arithmetic Abilities of Children With 22q11.2 Deletion Syndrome Aged From 4 to 11 Years Old

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04373226

Acronym

ARITH22

Enrollment

Registered

2020-05-04

Start date

2020-09-16

Completion date

2023-04-14

Last updated

2025-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

22q11.2 Deletion Syndrome

Keywords

22q11.2 deletion syndrome, arithmetic, magnitude representation, children

Brief summary

The study ARITH22 will investigate the role of visuo-spatial attention on arithmetic abilities of children with 22q11.2 deletion syndrome.

Detailed description

Children with 22q11.2 deletion syndrome often have arithmetic learning disability because of magnitude representation impairment. Previous works suggested that magnitude representation impairment could be a result of endogenous visuo-spatial attention dysfunction in 22q11.2DS. Nevertheless this relationship is still poor explored. The influence of visuo-spatial abilities on arithmetic achievement could also be modulated by developmental age. The study ARITH22 will test these hypotheses thanks to magnitude comparisons tasks, in children with 22q11.2 deletion syndrome and matched children without developmental disease.

Interventions

BEHAVIORALMagnitude comparison tasks and neuropsychological testing

neuropsychological testing (ZAREKI-R) and magnitude comparison tasks with stimuli of different types (visual, visuo-spatial)

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Intervention model description

Monocentric study with two parallel groups

Eligibility

Sex/Gender

ALL

Age

4 Years to 11 Years

Healthy volunteers

Yes

Inclusion criteria

* Diagnosis of 22q11.2 deletion syndrome or no developmental disease * Aged from 4 to 11 years old * French language

Exclusion criteria

* Diagnosis of intellectual deficiency according to DSM 5 criteria * Drug prescribed for somatic condition that could influence cerebral functioning

Design outcomes

Primary

Measure	Time frame	Description
Percentage of impaired scaled score	single day	percentage of impaired scaled score at ZAREKI-R

Secondary

Measure	Time frame	Description
Percentage of correct responses	single day	percentage of correct responses in magnitude comparisons tasks
Mean reaction time	single day	mean reaction time in magnitude comparison tasks

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026